INTRODUCTION
Recognized as one of the major accomplishments in molecular biology, production of monoclonal antibodies (MAbs) to an almost endless variety of antigenic substances has rapidly created an expanding role for these reagents in research and in clinical diagnosis. Because they can be prepared to most major human pathogens, MAbs have provided the means for developing a number of highly specific and reproducible immunological assays for rapid and accurate diagnosis of infectious diseases (67) . Not only will assays using MAbs replace many of the methods currently available, but use of these antibodies will also permit unique and novel approaches to rapid and accurate diagnosis of parasitic, autoimmune, and malignant diseases.
Although MAbs are routinely produced today, their production is not without limitations. Time-consuming steps are necessary to select a clone that produces an antibody with the desired sensitivity and specificity. For 80, 148) . The standard sequence of production events includes animal immunization, cell fusion, selection of hybrid cells, and screening and selection of the hybridoma cells that produce the desired antibodies (Fig. 1) . A growing number of innovative methods has been used to increase both the yields of hybrid cells and the probability for successful isolation of the desired antibody.
As stated above, immunization is the initial step in obtaining the necessary antigen-activated lymphocytes for fusion. Standard protocols for these immunizations are often successful and have been described previously in detail (80, 148) . Numerous in vivo immunization techniques have recently been reported that present an antigen directly into the spleen or lymph nodes (122, 136) and allow the use carbonate-bicarbonate buffer, pH 9.6. These antigen-bearing particles were used in lymphoproliferation cultures in vitro.
An increasingly useful method in hybridoma production is in vitro immunization (137) . This technique has the practical advantage of requiring short immunization periods and the use of small quantities of an antigen. Although considered difficult and labor intensive relative to in vivo methods, the in vitro immunization route has allowed generation of MAbs to previously nonimmunogenic (23) or weakly immunogenic
(1) antigens. Some important factors for the in vitro activation of B lymphocytes include the use of lymphokines, which are usually obtained in thymocyte-conditioned medium (125, 137) , medium supplementation with mitogens (8), anti-Tsuppressor cell drugs, and insoluble antigen matrices (23) . Also, the use of sera from different animal species, specified lots of sera, or serum-free medium supplemented with 2-mercaptoethanol and ethanolamine (137) has been shown to be important for in vitro culture and immunization.
Specific hybridoma cell production has been enhanced by combining a standard in vivo immunization protocol and adoptive transfer of immune spleen cells or adoptive transfer of in vitro activated cells into a sublethally X-irradiated syngeneic recipient, followed by administration of the antigen (51) . Although these methods do not increase the total numbers of specific hybrids, apparently they increase the frequency of hybrids per number of cells cloned, thereby saving time and effort.
Cell-cell fusion has deviated little from the original methods described by Kohler and Milstein (84) . Different (56) . A variety of different-molecular-weight PEG preparations has been used to perform cell fusions; midrange PEG (average molecular weight, 1,500 to 4,000) is used most often. Another consideration in the use of PEG is the toxicity of each lot. The toxicity may be tested by exposing myeloma cells to a sample of a PEG solution and assessing the effect on (56) .
Critical to the formation of stable immortal antibodysecreting hybrid cell lines is the choice of the myeloma cell line used for cell fusions. Several myeloma cell lines, including both murine and human cells, have been isolated which are non-antibody producers (79, 154) . Hybridoma produc-Q QQ r..
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tion from human-murine and human-human fusions are becoming more common. Hybridomas generated by using a murine myeloma designated FOX-NY have been selected with adenine-aminopterin-thymidine-supplemented medium (161) in place of hypoxanthine-aminopterin-thymidine-supplemented medium. The selection is based on cells acquiring adenine phosphoribosyltransferase gene rather than the hypoxanthine phosphoribosyltransferase gene. The FOX-NY cell line, combined with immune lymphocytes derived from the RBF/Dn mouse strain, may be used commercially only under a licensing agreement from Hyclone Laboratories (Logan, Utah). Its use, therefore, is subject to economic consideration and the potential limitation of failure of the mouse strain to respond to specific antigens.
Screening hybridomas for the desired antibodies is the final step in MAb production. This and subsequent selection steps may become extremely labor intensive, the work expanding with each cell cloning. If the antigen, or perhaps the epitope, is well defined, then a screening procedure may be developed to eliminate nondesirable antibodies quickly. Techniques such as Western blotting and enzyme-linked immunosorbent assay (ELISA) can be used to distinguish reactivity to specific antigenic molecules. Nonelectrophoretic blotting of antigens on nitrocellulose and passive binding on polystyrene or polyvinyl chloride 96-well plates are frequently used to screen large numbers of hybridoma culture supernatants rapidly. Highly specific, affinity-purified anti-antibody-enzyme conjugates can be used to screen for antigen binding and simultaneously select for specific MAb isotypes. For example, immunoglobulin G2a (IgG2a), which is stable and easily purified, may be the most appropriate immunoglobulin to use for commercial ELISA reagents that require a long shelf life. Once several likely candidates have been selected, antibodies may be further screened for relative affinity. We have used a standardized checkerboard ELISA, testing increasing dilutions of antibodies with increasing dilutions of antigens, and the comparative sensitivity of antigen-antibody binding in the presence of agents that disrupt the tertiary structure of proteins, such as thiocyanate, to select for the best antibody.
Although the cost of producing a desired MAb can vary tremendously, the basic overhead cost comes primarily from extensive use of tissue culture facilities and the need for personnel with specialized training. Unless human lymphocytes are used, small-animal facilities must be available. For each reagent system, cost varies depending on both the antigen and the requirements established for use of the antibody. As mentioned above, the hybridoma antibody response to specific antigens is highly variable and all procedures beyond the standard ones increase expenses, time, and labor. Moreover, weakly immunogenic antigens may require immunization of numerous strains of mice or use of in vitro techniques. The lower efficiency of many of the alternative immunization procedures, combined with the need for elaborate antigen preparations (when not available commercially), may require even more time, equipment, and expense to develop an effective MAb. Additional costs are incurred in the screening process and can range from use of simple ELISA procedures to the more involved Western blot, ELISA, and radioimmunoassay (RIA) methods. However, once a hybridoma cell line is established, it should become permanently available. Most clinical laboratory standard procedures that use MAbs require only microgram or nanogram amounts of immunoglobulin per test.
Scale-Up Production of MAbs
To supply MAbs for use in clinical laboratories, gram quantities of purified MAbs must be produced. Assays using MAb reagents to detect a variety of analytes, infectious agents, and cell antigens are being performed in increasing numbers. The amount of purified MAb needed to perform 10 million ELISAs, using 0.1 to 1 jxg per test, is in the range of 1 to 10 g. Less sensitive assays, like the fluorescent-antibody test and agglutination assays, require 10 to 100 times that amount. In our experience, the average MAb yields obtained from mouse ascites fluid are between 1 and 10 mg/ml, depending on the hybridoma cell. Using an average yield of 5 ml of ascites fluid per animal, from 20 to 200 mice would be required to produce 1 g of antibody. As of 2 years ago, the cost to produce 1 liter of start-up ascites fluid was $5,000, including complete antibody characterization and assurances for the safe disposition of the cell line for production availability. Although the price of this raw material has probably increased in the last 2 years, the cost of nonpure MAbs ranges between $500/g and $5,000/g.
Depending on the antibody and its specific application, additional costs are incurred during the purification process. If the antibody is of the appropriate isotype, it can be highly purified with staphylococcal protein A affinity columns. Antibodies must be extremely pure if they are to be used for enzyme conjugation, but for other uses, e.g., in agglutination tests, they can be less pure and may be processed by methods such as ammonium sulfate precipitation and diethylaminoethyl column chromatography. In a comparison of protein A, ammonium sulfate-diethylaminoethyl and hydroxyapatite methods for MAb purification, it was found that protein A generally provided the highest yields and purity with MAb isotypes that bind to protein A (104).
High-Yield Production Average MAb yields from standard cell culture supernatants are between 1 and 20 mg/liter. For the manufacture of assay reagents requiring 100-g and higher amounts, a new technology was needed. Over the past decade, industry has developed a variety of large-scale culture technologies to meet the needs of large-volume production. The cost to produce large volumes of MAbs is inversely proportional to the total number of grams required. For example, at kilogram levels, the price is approximately $500/g, whereas prices for 1 to 10 g are in the range of $50,000 or greater per g (44) .
The success of in vitro techniques for growing hybridoma cells with high MAb yields is based primarily on two factors: (i) use of chemostats to feed the growing cells continuously with medium maintained with optimum pH, 02 content, and nutrients and (ii) development of several different types of culture vessels and systems for high-density cell growth. An excellent review of these in vitro cell culture techniques has been published (44) . In addition, in a number of the in vitro culture systems, serum-free medium or reduced serum concentrations are used. Modifications of the method and culture conditions have been described for growing and maintaining high cell density cytostatic cultures (21) . Problems encountered when large culture vessels and large volumes of medium are used have been reduced by application of a microencapsulation technique described by Lim and Sun in 1980 (97) (21) .
Other culture systems that have been used successfully in recent years include hollow-fiber module culture chambers that deliver nutrients by artificial capillaries (4) and a fiberbead matrix used either as packed beds or stirred slurries (78) . Both systems, used in combination with chemostats and perfusion systems, can provide decigram to kilogram lots of MAbs, or they can be scaled down for production of smaller quantities. Cost and MAb yield depend on the individual growth characteristics of the hybridoma cells and the relative amounts of antibody they produce per cell. As with ascites-produced antibodies, additional costs are incurred by the need to purify the antibody. Purification is greatly simplified with in vitro MAb production when serumfree medium can be used.
MAbs versus Polyclonal Antibodies
Production of MAbs and production of polyclonal antibodies are comparable in several aspects. Both materials require animal immunizations and care and maintenance of the production systems plus screening, selection, and preparation of the final product, i.e., the antibodies. Although the appropriate specific uses of MAbs or polyclonal antibodies will be discussed later, from a production point of view, MAbs generally cost more to develop, whereas polyclonal antibodies cost more to scale up and are less reproducible from lot to lot than are MAbs. Moreover, with polyclonal antibodies there is the additional cost of affinity purification to obtain high specificity, since most of the antibodies in these antisera are nonspecific. The purification is often technically difficult and, depending on the antigen, may be expensive as well. Therefore, cost varies according to the purity necessary and the total amounts of the antibody required.
TRENDS IN USE OF MAbS FOR IN VITRO DIAGNOSTIC TESTS
Hybridoma technology is well recognized as a significant development in our ability to produce and characterize homogeneous serologic reagents specific for many antigens. Among the positive features of MAbs are that they (i) have defined sensitivity and specificity, (ii) enhance other diagnostic technologies (e.g., enzyme immunoassays, latex agglutination, and fluorescence immunoassays), (iii) decrease diagnostic reaction times, (iv) are specific for multiple organism serotypes in cocktail configuration, (v) are amenable to engineered assays (e.g., MAb-polyclonal antibody combinations and MAb-deoxyribonucleic acid (DNA) probe configurations), (vi) are a consistent and reliable source of reagents (MAbs), (vii) allow for fine tuning of proportions of immunoglobulins directed at a given antigen in the diagnosis of current (acute) diseases, and (viii) may be applied beyond diagnostics (e.g., in therapy). Among their negative features are that they (i) have a narrow range of reactivity, (ii) have unfavorable affinity characteristics, (iii) may show biological cross-reactivity (e.g., with erythrocyte membranes), and (iv) display problems inherent in homogeneity; i.e., limited biological functions and sensitivity to inactivation, and (v) MAbs against weak immunogens are still difficult to obtain.
(Based on data from R. S. Kreisler and R. H. Yolken (185 [63a] ). Sensitivity is greater than those of latex agglutination and ELISA (assay dependent), and specificity is assay dependent. On the other hand there is a lack of total automation, the tests are labor intensive, there is nonspecific (background) fluorescence interference, the sensitivity is comparable to that of ELISAs in some cases, and a trained technician is necessary.
Particle Agglutination
The advantages of using latex particles as the solid-phase component for passive agglutination tests have been recognized by many workers. Besides excellent chemical stability, the surface of the particles contains no antigens that are recognized immunologically. Commercially available from a number of sources, these particles permit technology that is rapid, simple to perform, easy to read, and inexpensive (107) . Antibody-coated latex has been used for both manual and instrument-related methods, most commonly in the basic slide agglutination procedure. When used properly, this highly sensitive test can readily detect viable organisms, as well as soluble or cell-free extract material from body fluids, e.g., urine and cerebrospinal fluid (CSF).
Latex test performance depends primarily on the properties of the antibodies used in the coating process. Although most latex procedures that have been described have used polyclonal antisera, latex agglutination tests using MAbs are now emerging (140) conjugates are stable for prolonged periods under various conditions. Direct or indirect IFA procedures that are in regular use in many laboratories include rapid identification of group A streptococci; rapid and specific diagnosis of rabies virus in tissue; identification of enteroviruses, respiratory viruses, herpes simplex virus, arboviruses, rickettsiae, and chlamydiae, either isolated in culture or examined directly in clinical material; the highly specific fluorescent treponemal antibody-absorption test for syphilis; and rapid identification of Legionella pneumophila in tissues and exudates.
There are numerous pitfalls in the application of immunofluorescence to detect microorganisms. For instance, the procedures must be performed by workers who are well trained in the meticulous technique and have a strong background in serology and microscopy. The procedures must be closely monitored at all times by including positive and negative controls. Also, reagents must be rigidly standardized and their specificity must be checked regularly. In short, the IFA method should not be used as a substitute for conventional procedures, but rather as an adjunct to these tests.
IFA identification of microorganisms has improved considerably in recent years because of the availability of MAbs. When using reagents prepared to a variety of organisms, several workers have found that IFA assays that use MAbs are diagnostically superior to assays that use polyclonal reagents. For example, Nahm et al. (116) (55, 155) and at the University of California at Los Angeles (48) confirm that this MAb test has improved specificity and increased sensitivity for CMV diagnosis when compared with recovery of the virus by culture. MAbs against RSV have been used to detect the virus in nasopharyngeal aspirates. Fifty-two strains of RSV were isolated in cell culture from 100 infants with acute respiratory illness (14) . When compared with the combination of a polyclonal IFA test and cell culture, a sensitivity of 79% and a specificity of 100% were provided by IFA using a MAb against the RSV nucleoprotein. In another study (81) , comparisons between IFA using a MAb and cell culture of specimens from 252 patients yielded 93% agreement for one particular MAb. (17) . The enumeration and tissue distribution of functionally distinct cell populations that are labeled by MAbs have been described for liver diseases, renal diseases, cancer, and transplant rejection (181) . MAbs have been extensively used to characterize, classify, and diagnose human lymphoproliferative diseases (127, 181) . For the immunodiagnosis of tumors, MAbs to CEA, a-fetoprotein, and melanoma-associated antigens, for example, have been produced and are being used in studies of solid-tumor tissues (J. J. Thompson, M. Herlyn, and Z. Steplewski, abstract, Lab. Invest. 44:66A). Attempts have also been made to develop MAbs capable of discriminating between human tissue-specific markers (181) .
The presence of microorganisms or their products in tissue biopsy specimens can be confirmed by immunohistochemical techniques using MAbs. For example, MAbs to an early antigen of CMV have been used for diagnosis of CMV infections within 1 h after inoculation and centrifugation of shell vials that contain cover slips with monolayers of human diploid fibroblast (MRC-5) cells (155) .
Detection and localization of microorganisms in tissue samples often require some form of specimen pretreatment to expose or release the relevant antigen or to eliminate some factor(s) that can interfere in the test. Specimen material, such as solid-tissue samples, serum, and pericardial, synovial, and amniotic fluids may have to undergo pretreatment; appropriate methods are described elsewhere (49, 107) . Moreover, direct testing of specimen material has been reported to be improved considerably when the assay used incorporates MAbs. Using IFA with MAbs to detect Pneumocystis carinii directly from bronchoalveolar lavage specimens, Kovacs brightened considerably by the availability of MAbs (Table  3) . For example, tests using MAbs have both higher sensitivity and higher specificity for detecting rotavirus than do commercially available tests using polyclonal antibodies (68) . MAbs used in latex agglutination assays are sufficiently sensitive to detect group B streptococcal antigen in CSF and concentrated urine specimens (140) . As already noted, the major advantages of MAbs are their specificity and the consistency of the supply of reagents. The ability to select hybridomas making antibodies of the desired specificity and to discard those not of interest provides the monospecific reagents. Furthermore, pure antigen preparations are unnecessary in the production of MAbs, since one can select clones producing antibodies of the desired specificity.
One possible drawback of MAbs in diagnostic use is that the antibodies are developed to small, single epitopes on the antigens. That is, if the antigen is a high-molecular-weight protein, the MAbs directed to the antigen may appear to be of low affinity because, by definition, high-avidity polyclonal 95 antibodies to a large antigen must react with many epitopes. It has been suggested that a pool of MAbs directed to different epitopes would improve the avidity of MAbs for diagnostic purposes. Also, it is possible to produce and select MAbs with extremely high affinities, given enough time and effort.
The use of MAbs to identify and characterize antigens contained in complex mixtures is without equal. MAbs are excellent tools as probes for identifying antigens empirically, as well as providing the means to isolate the molecule for characterization. Although this review will not discuss methods for describing newly identified antigens, the Western blot method in combination with MAbs is often used (57, 123) . Also, affinity chromatography with MAbs covalently attached to a solid phase may be used to purify and isolate antigens.
ELISAS Principle
ELISAs have become so widespread that most fields of diagnostic medicine use them in some manner. This section will focus on application of ELISAs in clinical microbiology, in particular, those assays that use MAbs. Many excellent reviews and books are available which cover the extensive ELISA development using polyclonal antibodies (20, 26, 33, 71, 89, 118, 141, 176, 185) .
ELISAs that have been developed for microbiological applications are primarily solid-phase procedures (also called heterogeneous assays) in which one immunological binding component (i.e., either the antibody or the antigen) is bound to a solid surface. Although numerous procedural variations have been described, the basic principle of the assay can be summarized as shown in Fig. 2 . In both of these schemes, the sample comes in contact with the solid-phase binding component, and the enzyme-labeled antibody component is added either sequentially or concurrently. The binding reactions are followed by a separation-washing step to remove excess label. Enzyme substrate is then added, and the enzyme-catalyzed reaction product is detected either visually or spectrophotometrically.
MAb Application for Immunodiagnosis
The basic ELISAs were developed primarily with polyclonal antibodies, and these have not (88) . When the test was compared with the use of a polyclonal antibody, the specificity and, to some extent, the sensitivity of this antibody test was reported to be improved.
Occasionally, the specificity of MAbs can be a limitation if multiple strains or types of organisms exist in the clinical specimen and the antibody chosen for the assay is unable to detect all types. However, this problem can be overcome by using either a mixture of MAbs (cocktails) or finding an antigenic determinant that is shared by all strains or types of a species of microorganism. Examples of the need for MAb cocktails include HSV typing (121, 143) , chlamydial serovar detection (11, 12) , and staphylococcal enterotoxin detection (166) .
In certain cases, the preferred antibody pair has been a combination of both a polyclonal antibody and a MAb. Wolters et al. (183) described an assay for HBsAg using a MAb on the solid phase and a polyclonal enzyme-labeled sheep anti-HBsAg antibody. Shigella toxin has been detected in an assay also using a MAb on the solid phase and a polyclonal antibody-enzyme conjugate (36) . The reverse combination has been used to develop an assay for direct detection of HSV antigen. This procedure used polyclonal rabbit anti-HSV antibody on the solid phase and a MAbenzyme conjugate (2). A polyclonal antibody capture and MAb conjugate combination has also been described for use in an assay for toxic shock syndrome toxin (180) and a direct antigen detection procedure for Haemophilus influenza (16) .
Homogeneous Assays
In the homogeneous ELISA, all reagents are liquid phase. Such assays have only recently become commercially available. The principle of one such homogeneous ELISA (Microgenics, Inc., Concord, Calif.) involves a genetically engineered P-galactosidase component that consists of subunits and a linker molecule that allows the subunits to assemble and become active. An antigen to be assayed is covalently bound to the linker molecule so as not to inhibit its function unless an antibody binds to the antigen. The test format consists of the enzyme subunits, the linker moleculeantigen conjugate, and a predetermined amount of MAb to inhibit assembly of the enzyme subunits. When free antigen in a specimen is added to the reaction and binds to the MAb, the linker molecule remains functional and the enzyme subunits assemble and hydrolyze the substrate, thereby indicating the presence of the antigen in the specimen.
The most significant drawback of this homogeneous assay is the limited size of the antigen that can be conjugated to the linker molecule. The problem may be overcome by using polypeptide fragments with defined epitopes from an anti- 
Novel Test Systems and Assays
Of current interest to many clinical microbiologists are the novel delivery systems for detecting a variety of biological products. Many clinical microbiology or laboratory throwaway journals have advertisements extolling one or more of these systems as being rapid, accurate, cost-effective, and easy to use. These immunoenzymatic assays incorporate a common technology with unique design features that permit direct specimen testing. All use a type of filter membrane that serves as the primary site where the reaction between the antigen and antibody takes place. The series of reaction steps usually includes exposure of the specimen to the filter, addition of anti-antigen enzyme-labeled antibody, and exposure to the enzyme substrate, interspersed with appropriate wash steps. The entire procedure takes approximately 10 min, including the development of a color dot or symbol signifying a positive reaction. The primary difference between these test systems is how the filter membrane functions within the respective test cartridge.
Both Abbott Laboratories (North Chicago, Ill.) and Hybritech immobilize their capture MAb or polyclonal antibody on the filter, whereas for their solid phase, the Murex and Syva/Syntex systems use latex particles coated with the appropriate MAb or polyclonal antibody which are directly poured onto the filter membrane. Latex particles coated with an antigen also can be used with the latter systems (SUDS and AccuPoint) when assaying for a specific antibody. With the technology of microsphere filtration, the test cartridges of the SUDS and AccuPoint systems are basically filtration units that trap the coated latex particles. In this regard, the SUDS and AccuPoint test cartridges are perhaps best described as being nondedicated reaction filter devices, whereas the Abbott TestPack and Hybritech TANDOM and ICON test cartridges are dedicated reaction filter devices.
Besides their applications in clinics or physicians' offices, the advantages of these test systems are speed, simplicity, ease of interpretation, accuracy, relative cost effectiveness, and perhaps more importantly, the ability to be used directly with a specimen. Incorporation of MAbs appears to provide higher sensitivity and specificity than do standard culture systems. For example, the Hybritech Strep A ICON test was used to test 1,016 throat specimens for group A betahemolytic streptococci directly (126) . In this study, both the test and culture were negative in 829 (81.6%) specimens and in 164 (16.1%) cases both were positive. False-positive results were described in 9 (0.9%) cases, and 14 (1.4%) false-negative results were noted. It is conceivable that incubation of control cultures in a nonanaerobic environment could have accounted for the elevated test kit sensitivity values compared with those in which more stringent culture conditions were used. The false-negative results were attributed in part to use of one swab for both culture and ELISA. This test was easy to perform and read, and the investigators felt it could be very useful in physicians' offices and clinics.
Schwabe et al. (151) divided into two general steps: production of a nucleic acid probe and hybridization of the nucleic acid probe with the target nucleic acid. Production of a nucleic acid probe originates with isolation of a specific nucleic acid fragment. The minimum sensitivity of an individual nucleic acid hybridization probe depends on the size of the genomic target and the percentage of homology between the probe and the target (39) . With the use of ribonucleic acid probes, the sensitivity of the assay may increase (39, 42, 62, 70) . For production of test probes, specific sequences are usually amplified by cloning into the appropriate vector (i.e., a plasmid or cosmid). After isolation of the cloned sequence with restriction enzymes, nonradioactive or radioactive labels are attached. The label fragment is then denatured and used as a probe.
There are three categories of nucleic acid hybridization techniques: solid-phase hybridization, solution phase hybridization, and in situ hybridization (22, 70, 92, 110, 157) . Solid-phase hybridization is perhaps the most widely used technique. However, once the target nucleic acid is immobilized on the nitrocellulose filter only a portion of it is accessible to the probe (39) . When solution phase hybridization is performed, the target nucleic acid probe is allowed to anneal with a specific probe in an aqueous environment. The target nucleic acid is fully accessible to the probe, potentially increasing the sensitivity of the assay (39, 70) . In situ hybridization involves the use of thin sections of tissue or host cells fixed to glass slides (39, 157, 170) . The method is cumbersome and appears to be less sensitive than other methods of hybridization (39, 157) . 4.4-megadalton (MDa) plasmids isolated from Neisseria gonorrhoeae. Sensitivities of 99% (2.6-MDa probe) and 96% (4.4 MDa probe) were observed with a filter hybridization protocol (128) . After 3 days of autoradiography, Totten et al. (168) observed a sensitivity and a specificity of 89 and 100%, respectively. The 2.6-MDa probe did not work well in cervical and rectal infections, presumably because of low concentrations of organisms (168) . Additionally, some gonococcal isolates did not carry the 2.6-MDa plasmid (128, 168) . The sensitivity and specificity of probe assays appear to be comparable to those generated with a commercial polyclonal ELISA for detection of Neisseria gonorrhoeae. Sensitivities ranging from 80 to 99% and specificities ranging from 86 to 98% have been reported with the Gonozyme assay (105, 117, 147, 163 (130) .
Nucleic acid probes constructed for detection of chlamydiae in clinical specimens generated sensitivity and specificity values of 91 and 83%, respectively, when compared with culture (74, 76) . When compared with an IFA assay, a sensitivity of 92% and a specificity of 85% were observec (74) . A sensitivity of 92% and a specificity of 98.4% were observed with the IDEIA chlamydia test, an amplified ELISA using a MAb to detect the genus-specific Chlamydia antigen (28, 135) .
Enterotoxigenic Escherichia coli strains have been identified by nucleic acid hybridization (38, 102, 114) . When compared with detecting enterotoxin production in the Y-1 adrenal cell and suckling mouse assays, the DNA hybridization technique had a sensitivity of 94% and a specificity of 100% (38) . Studies performed by Klipstein et al. (82) and Ristaino et al. (144) disclosed that the sensitivity of ELISA for detection of heat-stable and heat-labile toxins was equal to or greater than the sensitivity of tissue culture assays.
Other agents for which nucleic acid probes have been developed and analyzed include viruses such as CMV (30, 100, 150, 158) , HSV (34, 52, 91, 149) , human papillomavirus (179), adenovirus (60, 174) , hepatitis B virus (18), EpsteinBarr virus (24) , and HIV (65) . Nucleic acid probes for bacteria such as Salmonella typhi (145) , legionellae (40) , Vibrio cholerae (167) , and campylobacters (167) also have been developed. Nucleic acid hybridization offers a distinct potential advantage for high specificity and good sensitivity. With radiolabeled probes, levels of 1 to 2 pg of nucleic acid can be detected without cross-reactivity with closely related species (18, 31, 39, 70) . One distinct disadvantage of nucleic acid probe assays is the requirement for a radiolabeled probe to generate the necessary sensitivity. A reduced level of sensitivity may be observed when nonradiolabeled probes are substituted for radiolabeled probes (39, 70, 93 2-acetylaminofluorene, use of polymeric alkaline phosphatase, and use of solution hybridization may improve the sensitivity of nucleic acid probes (52, 93, 106, 175) . In this regard, Gen-Probe (San Diego, Calif.) has incorporated solution hybridization into its nucleic acid probe assay.
Although nucleic acid probe technology looks extremely promising, there are several limitations that must be overcome before wide-scale commercial use becomes possible (5, 39, 70) . (i) Radiolabeled probes will have to be replaced by nonradiolabeled probes. (ii) Sensitivity must be improved while reducing assay time to within 2 to 4 h. (iii) Probes with a range broad enough to detect all members of a given species must be developed. (iv) Assays need to be automated to eliminate the large number of manual procedures required for each specimen. Some positive aspects of nucleic acid probes are the following (source, Robert S. Kreisler,): (i) high specificity for species identification, with no inherent problems detecting different strains (serogroupings, etc.); (ii) good sensitivity; (iii) not serotype dependent (MAbs are at a comparative disadvantage because antibody pools are required); (iv) ability to produce large quantities of monospecific reagents by cloning; (v) amenability to both in situ and filtration processing; (vi) stable DNA molecule allows collection of specimens at remote locations, and processing can occur weeks to months later and is amenable to the field situation; (vii) stable shelf life (in nonisotopic format); (viii) multiple samples can be identified simultaneously. The negative characteristics of DNA probes include the following: (i) technical problems in directly probing some clinical materials and some nonspecific binding when nonisotopic labels are used; (ii) sensitivity of probes is diminished when reacting directly with clinical material as compared with colony hybridization; (iii) sensitivity good but not yet equivalent to ELISA and not as rapid (however, sensitivity is improved when the solution phase process is used; increased amount of available DNA enhances the kinetics of the reaction); (iv) clinical samples may require some purification before analysis (for example, there is still a high rate of false-positive tests when direct testing of stool filtrate for Campylobacter jejuni is attempted; however, this problem is currently being resolved for most specimen types); (v) time required for most assays, about 1 day (although this timeframe is being reduced); (vi) short shelflife of isotopic labels; (vii) labor intensiveness. Current MAb assays appear to be less complex, equal in sensitivity and specificity, and require less time than current nucleic acid probe kits. However, simplification or improvement (or both) of nucleic acid probe assays could easily overcome the gap that exists between these assays. CONCLUSIONS Hybridoma technology has had and will continue to have a major impact on the diagnosis (and treatment) of human disease. For diagnosing infectious disease agents, this technology has the potential to alter significantly the methods used in most clinical microbiology laboratories. In many instances, specimens that once required culture are now tested directly by rapid, easy-to-use, economical, and accurate methods. This technology will be used both in large laboratories and in outpatient laboratories (e.g., physicians' offices). Because the latter may be the major sites for test use, appropriate education and training must be available to assure proper use and interpretation of MAb-based systems. Indeed, the medical diagnostics industry, the American Society for Microbiology, the National Committee for Clin- 
